undamentalytics Newsletter
Sign in

Healthcare Triangle, Inc. (HCTI) stock

Add to watchlist

Add holding +

NASDAQ: HCTI Nasdaq Health Care Technology

C+ Fundamentals grade

Healthcare Triangle, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: share count (2m) is 0.14x the cover-page count (15m).

Price vs value

Under review: share count (2m) is 0.14x the cover-page count (15m). We'll show the comparison once resolved.

Healthcare Triangle, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds4 adding, 6 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Healthcare Triangle files

Where Healthcare Triangle stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $26m, up 116.4% on a year earlier, faster than the 77.5% growth a quarter earlier. That growth ranks 2 of 19 among the health care technology companies we cover. Free-cash-flow margin rose to -62.4% from -69.9% a year earlier. Operating margin narrowed to -57.4% from -37.3%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 6 financial-health checks.

Our model value for Healthcare Triangle is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Healthcare Triangle, Inc.'s trailing-twelve-month revenue grew 116.4% year on year, with a free-cash-flow margin of -62.4%. Where it stands out: revenue growth of 116.4% ranks 3 of 23 health care technology companies we cover. Where it lags: free-cash-flow margin of -62.4% ranks 19 of 22 health care technology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 116.4% (+38.9pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 116.4% over the last 12 months, against a median of 8.8% for health care technology companies we cover.
  • Growth speeding up. The growth rate is 38.9 points higher than a quarter earlier.

Things to watch

  • Loss-making. Operating margin is -57.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 20.1 points on a year ago.
  • Burning cash. Free cash flow was -62.4% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 124% and a beta of 1.8 against the S&P 500.
  • Below peers: gross margin. Gross margin of 21.5% ranks 12 of 14 health care technology companies we cover (median 58.2%).
  • Below peers: days sales outstanding. Days sales outstanding of 88 days ranks 17 of 21 health care technology companies we cover (median 58 days).

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$26.58 against an average estimate of -$68.60: beat by 61.3%
Revenue
$9m, up 158.4% on a year earlier

Healthcare Triangle's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.1%
  • 1 week-27.2%
  • 1 month-65.7%
  • This year-99.3%
  • 1 year-99.9%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$25.7M
Operating margin
-57.4%
Net margin
-66.3%

Growth

Revenue growth
+116.4%
Change in growth rate
+38.9 pts

Cash

Free cash flow (TTM)
-$16M
FCF margin
-62.4%
Stock pay % of revenue
3.2%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Shareholder vote
  3. Agreement
  4. Agreement
  5. Share issue
  6. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Healthcare Triangle, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (2m) is 0.14x the cover-page count (15m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$5408280.00$537840.00$820206.00$294616.81$759.60
Market value$15.92tn$1.99tn$3.43tn$104m$47m
+ Net debt (− = net cash)$439000$1m$4m−$20000$3m
Enterprise value$15.92tn$1.99tn$3.43tn$104m$50m
Multiples
Price / sales n/mn/mn/m8.9x3.4x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$204.60 +93% $39m +180%
Next −$63.60 +69% $41m +4%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −36.6% on 90 days ago. In the last 30 days, 0 analysts raised Healthcare Triangle, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Healthcare Triangle, Inc., last 90 days
−$400.00 −$300.00 −$200.00 −$100.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$322.60 Current fiscal year, 60 days ago: −$322.60 Current fiscal year, 30 days ago: −$322.60 Current fiscal year, 7 days ago: −$219.20 Current fiscal year, Now: −$204.60 −$204.60 Next fiscal year, 90 days ago: −$202.80 Next fiscal year, 60 days ago: −$202.80 Next fiscal year, 30 days ago: −$202.80 Next fiscal year, 7 days ago: −$15.60 Next fiscal year, Now: −$63.60 −$63.60

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$322.60−$202.80
60 days ago −$322.60−$202.80
30 days ago −$322.60−$202.80
7 days ago −$219.20−$15.60
Now −$204.60−$63.60

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$68.60 −$26.58 +61.3%
Dec 2025 −$240.00 −$370.00 −54.2%
Sept 2025 −$264.00 −$504.00 −90.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
1.4%
of tradable shares
Days to cover
0.06
at average volume
Short interest, 1 month
−47%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
70.7%
of shares
Employees
40
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
HCTI−90%+53%−64%−100%−99%
Industry peers (median)−60%−25%−8%−27%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
HCTI17%42%42%33%9%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
HCTI−93%−57%−91%−100%−99%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 13, 2021: 100% from October 13, 2021 to November 2, 2026. Getting back needed a 215399900% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.98 – $3336.00
From 52-week high
−99.9%
vs 50-day average
−59.9%
vs 200-day average
−92.4%
Volatility (1 year)
124%
Beta vs S&P 500
1.84

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Healthcare Triangle, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Healthcare Triangle, Inc.
$0 $10M $20M $30M $40M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $37.4M Revenue (TTM), FY23 Q4: $33.2M Revenue (TTM), FY24 Q1: $27.5M Revenue (TTM), FY24 Q2: $21.9M Revenue (TTM), FY24 Q3: $16.6M Revenue (TTM), FY24 Q4: $11.7M Revenue (TTM), FY25 Q1: $11.3M Revenue (TTM), FY25 Q2: $11.9M Revenue (TTM), FY25 Q3: $12.9M Revenue (TTM), FY25 Q4: $13.9M Revenue (TTM), FY26 Q1: $20M Revenue (TTM), FY26 Q2: $25.7M $25.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $37.4M
FY23 Q4 $33.2M
FY24 Q1 $27.5M
FY24 Q2 $21.9M
FY24 Q3 $16.6M
FY24 Q4 $11.7M
FY25 Q1 $11.3M
FY25 Q2 $11.9M
FY25 Q3 $12.9M
FY25 Q4 $13.9M
FY26 Q1 $20M
FY26 Q2 $25.7M
Revenue growth, TTM YoY Healthcare Triangle, Inc.
-100% -50% 0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -14.5% Revenue growth, TTM YoY, FY23 Q4: -27.6% Revenue growth, TTM YoY, FY24 Q1: -38.5% Revenue growth, TTM YoY, FY24 Q2: -47.3% Revenue growth, TTM YoY, FY24 Q3: -55.7% Revenue growth, TTM YoY, FY24 Q4: -64.8% Revenue growth, TTM YoY, FY25 Q1: -58.9% Revenue growth, TTM YoY, FY25 Q2: -45.9% Revenue growth, TTM YoY, FY25 Q3: -21.9% Revenue growth, TTM YoY, FY25 Q4: 18.8% Revenue growth, TTM YoY, FY26 Q1: 77.5% Revenue growth, TTM YoY, FY26 Q2: 116.4% 116.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -14.5%
FY23 Q4 -27.6%
FY24 Q1 -38.5%
FY24 Q2 -47.3%
FY24 Q3 -55.7%
FY24 Q4 -64.8%
FY25 Q1 -58.9%
FY25 Q2 -45.9%
FY25 Q3 -21.9%
FY25 Q4 18.8%
FY26 Q1 77.5%
FY26 Q2 116.4%
Operating margin (TTM) Healthcare Triangle, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -45.9% Operating margin (TTM), FY23 Q4: -23.2% Operating margin (TTM), FY24 Q1: -22.6% Operating margin (TTM), FY24 Q2: -27.3% Operating margin (TTM), FY24 Q3: -34.0% Operating margin (TTM), FY24 Q4: -40.7% Operating margin (TTM), FY25 Q1: -39.3% Operating margin (TTM), FY25 Q2: -37.3% Operating margin (TTM), FY25 Q3: -45.2% Operating margin (TTM), FY25 Q4: -70.5% Operating margin (TTM), FY26 Q1: -60.0% Operating margin (TTM), FY26 Q2: -57.4% -57.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -45.9%
FY23 Q4 -23.2%
FY24 Q1 -22.6%
FY24 Q2 -27.3%
FY24 Q3 -34.0%
FY24 Q4 -40.7%
FY25 Q1 -39.3%
FY25 Q2 -37.3%
FY25 Q3 -45.2%
FY25 Q4 -70.5%
FY26 Q1 -60.0%
FY26 Q2 -57.4%
FCF margin (TTM) Healthcare Triangle, Inc.
-150% -100% -50% 0% 50% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY23 Q4: -6.5% FCF margin (TTM), FY24 Q1: -2.2% FCF margin (TTM), FY24 Q2: -1.8% FCF margin (TTM), FY24 Q3: 2.0% FCF margin (TTM), FY24 Q4: -9.2% FCF margin (TTM), FY25 Q1: -58.3% FCF margin (TTM), FY25 Q2: -69.9% FCF margin (TTM), FY25 Q3: -81.1% FCF margin (TTM), FY25 Q4: -119.0% FCF margin (TTM), FY26 Q1: -89.0% FCF margin (TTM), FY26 Q2: -62.4% -62.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -6.5%
FY24 Q1 -2.2%
FY24 Q2 -1.8%
FY24 Q3 2.0%
FY24 Q4 -9.2%
FY25 Q1 -58.3%
FY25 Q2 -69.9%
FY25 Q3 -81.1%
FY25 Q4 -119.0%
FY26 Q1 -89.0%
FY26 Q2 -62.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 31 35 46 33 12 14 26
Gross profit 9 11 11 1,070 1,070 1,235 6
EBITDA 2 −4 −13 −6 −4 −9 −13
Operating income 1 −5 −16 −8 −5 −10 −15
Net income 2 −6 −14 −9 −6 −9 −17
Diluted EPS $0.84 −$2.02 −$3.88 −$2.08 −$16909.30 −$152.30 —
Growth (year on year)
Revenue — +12.5% +30.1% −27.6% −64.8% +18.8% +116.4%
EBITDA — −298.8% — — — — —
Operating income — −555.3% — — — — —
Net income — −352.8% — — — — —
Diluted EPS — −340.5% — — — — —
Margins
Gross margin 27.4% 29.8% 24.6% — — — 21.5%
EBITDA margin 6.3% −11.2% −29.2% −18.5% −33.0% −65.4% −49.4%
Operating margin 3.8% −15.2% −35.6% −23.2% −40.6% −70.5% −57.4%
Net margin 7.5% −16.9% −31.3% −26.2% −51.0% −68.2% −66.3%
Free-cash-flow margin — — −11.8% −6.5% — −119.0% −62.4%
Cash flow
Cash from operations −1 −7 −5 −2 −1 −17 −16
Capital spending — — 0 0 — 0 0
Free cash flow — — −5 −2 — −17 −16
Stock-based pay — 0 0 0 0 0 —
Free cash flow after stock pay — — −6 −2 — −17 —
Balance sheet
Cash 1 2 1 1 0 8 2
Total debt 1 2 3 5 — 11 17
Net debt (negative = net cash) −1 0 1 4 −0 3 15
Diluted shares 3m 3m 4m 4m — — —
Returned to shareholders
Buybacks — — 0 — — — —
Total returned — — 0 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · June 30, 2026
What it owns · $74m
Short-term assets $10mLonger-term assets $64m
What it owes, and who funded it · $74m
Short-term liabilities $16mLonger-term liabilities $9mShareholders' equity $49m
  • Short-term assets cover short-term liabilities $10m of assets due within a year against $16m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $10m short-term assets against $9m of longer-dated liabilities.
  • More cash than debt $2m of cash against $14m of debt.
  • Debt below 40% of shareholders' equity Debt is 28% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$16m of operating cash flow against $14m of debt.
  • Operating profit covers interest at least five times over Operating income of −$15m against $424,000 of interest.

From Healthcare Triangle, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
1.8%
of revenue
Days sales outstanding
88 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated HCTI DRIO SOPH MNDR OPRX CCLD Median
Revenue, last 12 months $26m $21m $77m $8m $99m $129m $292m
Revenue growth, last 12 months 116.4% −22.6% 18.6% 1.2% −5.8% 15.1% 8.8%
Revenue growth, 3-year average −14.9% −7.6% — — 17.0% 0.8% 0.8%
Revenue growth, latest quarter 158.4% −3.6% — — −29.8% 16.4% 7.4%
Gross margin 21.5% 58.2% 67.4% 21.2% 73.2% — 58.6%
Operating margin −57.4% −151.6% −91.8% — 11.1% 7.1% −12.5%
Operating margin, 3-year average −40.6% −213.6% — — −6.8% −7.0% −18.8%
Net margin −66.3% −169.9% −102.2% −41.2% 4.7% 6.2% −12.5%
Cash from operations / revenue −62.4% −120.7% −46.5% −19.7% 18.7% 20.8% 9.7%
Free-cash-flow margin −62.4% −121.3% −47.2% −19.7% 18.6% 17.7% 9.2%
Free-cash-flow margin, 3-year average −44.7% −144.7% — — 8.7% 16.7% 8.2%
Stock pay / revenue 3.2% 33.6% 21.0% 19.9% 8.1% 0.3% 9.5%
Change in share count — 25.9% 2.2% 265.5% 2.5% 73.1% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 116.4% 8.8% 3 of 23
Change in growth rate Growth +38.9pp -0.3pp 3 of 23
Gross margin Profitability 21.5% 58.2% 12 of 14
Operating margin Profitability -57.4% -6.6% 16 of 22
Net margin Profitability -66.3% -12.5% 16 of 23
Free-cash-flow margin Cash generation -62.4% 10.6% 19 of 22
Stock pay as % of revenue Cash generation 3.2% 9.7% 5 of 22
Long-term debt as % of assets Balance sheet 11.0% 20.1% 7 of 15
Days sales outstanding Balance sheet 88 days 58 days 17 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Software Services $8.3M ▲ 75.9%
Managed Services and Support $5.4M ▼ 20.2%
Corporate Others $278,000 ▼ 3.5%
Corporate and Others $278,000 ▼ 3.5%

These categories overlap or exclude eliminations, so shares aren't shown.

From Healthcare Triangle, Inc.'s 10-K filed April 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$78,442
Institutions reporting
8
Shares held vs prior quarter
▼ 56.9%
Positions opened / closed
2 / 4

Top buyers and sellers, Q2 2026: 4 institutions bought and 6 sold ; the biggest buyer was Bank Of Montreal (+10K shares) and the biggest seller UBS Group AG (−32K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bank Of Montreal $36,200 20K 46.1% ▲ 100.0%
Geode Capital Management, LLC $21,674 12K 27.6% ▼ 4.9%
UBS Group AG $16,034 9K 20.4% ▼ 78.2%
Tower Research Capital LLC (TRC) $2,378 1K 3.0% ▲ 65.5%
Vanguard Capital Management LLC $1,555 1K 2.0% 0.0%
Barclays PLC $561 0K 0.7% New
Jpmorgan Chase & Co $38 0K 0.0% New
Danske Bank A/S $2 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Healthcare Triangle, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Healthcare Triangle, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Healthcare Triangle, Inc. in brief

What does Healthcare Triangle, Inc. do?
Healthcare Triangle, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Healthcare Triangle, Inc.'s stock ticker?
Healthcare Triangle, Inc. trades under the ticker HCTI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Healthcare Triangle, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Healthcare Triangle, Inc. reported revenue of $25.7M, 116.4% higher than a year earlier, according to its SEC filings.
What is Healthcare Triangle, Inc.'s free cash flow?
Healthcare Triangle, Inc.'s free-cash-flow margin is -62.4% of revenue over the trailing twelve months, ranking 19 of the 22 health care technology companies we cover.
Who are Healthcare Triangle, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bank Of Montreal, Geode Capital Management, LLC and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Healthcare Triangle, Inc.'s market cap?
On December 31, 2025, Healthcare Triangle, Inc.'s market capitalisation was about $47M and net debt of $2.9M. Market figures come from third-party market data and may be delayed.
How much debt does Healthcare Triangle, Inc. have?
Healthcare Triangle, Inc.'s debt-to-equity ratio is 27.6%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Healthcare Triangle, Inc.'s competitors?
In our Health Care Technology peer group, the companies closest to Healthcare Triangle, Inc. are Dariohealth Corp., Sophia Genetics SA, Mobile-health Network Solutions, Optimizerx Corp and Carecloud, Inc. The side-by-side comparison below sets their revenue, margins and growth against Healthcare Triangle, Inc.'s.